Journal
APPLIED RADIATION AND ISOTOPES
Volume 68, Issue 1, Pages 33-36Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.apradiso.2009.09.027
Keywords
Raloxifene; I-131; Iodogen; Rats; Uterus; I-131-raloxifene
Categories
Funding
- Ege University Research and Application Center of Science and Technology
Ask authors/readers for more resources
Raloxifene is a selective estrogen receptor modulator that produces both estrogen agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue. In the present study, raloxifene was labeled with I-131 by iodogen method and investigated for its radiopharmaceutical potential. Radiolabeling yield is 91 +/- 0.7%, as determined by radio thin layer chromatography (RTLC). Results of in vitro study indicated I-131-raloxifene has high stability (4 h) in serum. Biodistribution study was carried out with Albino wistar female rats. The result has shown that the radioiodinated raloxifene has higher uptake in uterus than breast and ovarian. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available